Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1

Status

Completed 48Recruiting 45Active not recruiting 30Terminated 23Unknown 5Not yet recruiting 5Withdrawn 4Enrolling by invitation 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 3Breast Cancer Metastatic 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cisplatin 122Carboplatin 120Drug Therapy 104Bevacizumab 101Capecitabine 96Oxaliplatin 95Radiotherapy 92Gemcitabine 88Paclitaxel 87tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 66Magnetic Resonance Spectroscopy 63Fluorouracil 61sintilimab 58Injections 57anlotinib 51Docetaxel 51Surgical Procedures, Operative 48130-nm albumin-bound paclitaxel 48fludarabine 45Pemetrexed 43Standard of Care 42Biopsy 42venetoclax 41Irinotecan 41lenvatinib 40Leucovorin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × ribociclib × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT07340658 2026-04-02

SIE-3

Rovi Pharmaceuticals Laboratories

Phase 3 Not yet recruiting
300 enrolled
Breast

Breast Neoplasms

NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Samsung Medical Center

Phase 2 Not yet recruiting
272 enrolled
Breast

Breast Cancer Metastatic

NCT07195227 2025-10-02

CADILLAC

MedSIR

Phase 2 Not yet recruiting
150 enrolled
Breast

Breast Neoplasms

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Hubei Cancer Hospital

Phase NA Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡